OncoCyte Corp (NYSEAMERICAN:OCX) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totalling 1,007,700 shares, a decline of 18.8% from the June 30th total of 1,240,400 shares. Approximately 3.3% of the company’s stock are short sold. Based on an average trading volume of 365,900 shares, the short-interest ratio is currently 2.8 days.
Shares of NYSEAMERICAN OCX opened at $2.09 on Thursday. OncoCyte has a 52-week low of $1.16 and a 52-week high of $6.92.
OncoCyte (NYSEAMERICAN:OCX) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01.
In other news, major shareholder Broadwood Partners, L.P. bought 1,000,000 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were purchased at an average price of $2.00 per share, for a total transaction of $2,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Biotime Inc sold 2,250,000 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $2.00, for a total transaction of $4,500,000.00. The disclosure for this sale can be found here.
Hedge funds and other institutional investors have recently modified their holdings of the company. Emerald Mutual Fund Advisers Trust bought a new position in shares of OncoCyte in the first quarter worth approximately $9,836,000. Virtu Financial LLC purchased a new position in shares of OncoCyte during the first quarter valued at approximately $114,000. Spark Investment Management LLC purchased a new position in shares of OncoCyte during the first quarter valued at approximately $159,000. Perkins Capital Management Inc. purchased a new position in shares of OncoCyte during the first quarter valued at approximately $99,000. Finally, Wells Fargo & Company MN raised its holdings in shares of OncoCyte by 77,522.4% during the second quarter. Wells Fargo & Company MN now owns 38,035 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 37,986 shares during the last quarter.
OncoCyte Company Profile
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Featured Story: How does equity income fit into an investing strategy?
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.